This study is testing two investigational drugs, D2C7-IT and 2141-V11, for adults newly diagnosed with a type of brain tumor called glioblastoma (GBM). Specifically, it's for those whose tumors have a certain genetic marker (MGMT unmethylated) and still show some disease after surgery. The study will first give D2C7-IT and 2141-V11 directly into the brain near the tumor. Afterward, 2141-V11 will be given as injections under the skin near the lymph nodes in the neck. The main goal is to see how long patients live after starting treatment. About 50 people are expected to join this study. The current recruitment status is unclear.

Study design

This study is an interventional trial with a planned enrollment of 50 participants. The phase of the study is not specified.

What's involved

You would receive a single infusion of D2C7-IT and 2141-V11 into your brain, followed by repeated subcutaneous injections of 2141-V11 for up to a year, alongside standard radiation therapy.

Compensation

Not stated in the trial record.

Follow-up

Your survival will be measured for up to 3 years after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.